The trading price of Infinity Pharmaceuticals, Inc. (NASDAQ:INFI) floating lower at last check on Tuesday, Feb 23, closing at $3.65, -9.32% lower than its previous close.

Get the hottest stocks to trade every day before the market opens 100% free. Click here now.

Traders who pay close attention to intraday price movement should know that it has been fluctuating between $3.2000 and $3.5400. The company’s P/E ratio in the trailing 12-month period was 0, while its 5Y monthly beta was 2.22. In examining the 52-week price action we see that the stock hit a 52-week high of $5.98 and a 52-week low of $0.6. Over the past month, the stock has suffered -4.45% in value.

Infinity Pharmaceuticals, Inc., whose market valuation is $312.04 Million at the time of this writing, is expected to release its quarterly earnings report Mar 01, 2021- Mar 05, 2021. Investors’ optimism about the company’s current quarter earnings report is understandable. Analysts have predicted the quarterly earnings per share to grow by -$0.16 per share this quarter, however they have predicted annual earnings per share of -$0.67 for 2021 and -$0.58 for 2022. It means analysts are expecting annual earnings per share growth of -0.19% this year and -0.13% next year.

On the technical side, indicators suggest INFI has a 50% Buy on average for the short term. According to the data of the stock’s medium term indicators, the stock is currently averaging as a 100% Buy, while an average of long term indicators suggests that the stock is currently 100% Buy.

Here is the average analyst rating on the stock as represented by 1.00 to 5.00, with the extremes of 1.00 and 5.00 suggesting the stock should be considered as either strong buy or strong sell respectively. The number of analysts that have assigned INFI a recommendation rating is 6. Out of them, 2 rate it a Hold, while 4 recommend Buy, whereas none assign an Outperform rating. None analyst(s) have tagged Infinity Pharmaceuticals, Inc. (INFI) as Underperform, while not any of them advise Sell. Analysts have rated the stock Overweight, likely urging investors to take advantage of the opportunity to add to their holdings of the company’s shares.

If we dig deeper into the stock’s outlook, we see that the stock’s PEG is 0, which symbolizes a positive outlook. A quick review shows that INFI’s price is currently -14.87% off the SMA20 and 8.28% off the SMA50. The RSI metric on the 14-day chart is currently showing 45.56, and weekly volatility stands at 8.75%. When measured over the past 30 days, the indicator reaches 13.15%. Infinity Pharmaceuticals, Inc. (NASDAQ:INFI)’s beta value is currently sitting at 2.22, while the Average True Range indicator is currently displaying 0.56. With analysts defining $2-$12 as the low and high price targets, we arrive at a consensus price target of $7.6 for the trailing 12-month period. The current price is about -39.58% off the estimated low and 262.54% off the forecast high, based on this estimate. Investors will be thrilled if INFI’s share price rises to $8, which is the median consensus price. At that level, INFI’s share price would be +141.69% above current price.

To see how Infinity Pharmaceuticals, Inc. stock has been performing today in comparison to its peers in the industry, here are the numbers: INFI stock’s performance was -9.32% at last check in today’s session, and +151.72% in the past year, while Zoetis Inc Cl A (ZTS) has been trading +0.05% in recent session and positioned +12.61% higher than it was a year ago. Another comparable company Takeda Pharmaceutical CO Ltd (TAK) saw its stock trading -2.65% lower in today’s session but was down -7.66% in a year. Furthermore, Catalent Inc (CTLT) showed a decline of -9.32% today while its price kept rising at 151.72% over the past year. Infinity Pharmaceuticals, Inc. has a P/E ratio of 0, compared to Zoetis Inc Cl A’s 46.79 and Takeda Pharmaceutical CO Ltd’s 21.38. Also during today’s trading, the S&P 500 Index has soared -0.93%, while the Dow Jones Industrial also saw a negative seesion, down -0.54% today.


The 2021 Backdoor Crypto Portfolio (free)

Even if you’re not actively in crypto, you deserve to know what’s actually going on...

Because while leading assets such as Bitcoin (BTC) and Ethereum (ETH) are climbing in value, a select group of public “crypto stocks” are surging right along with them. More importantly, these stocks are outpacing the returns these leading crypto assets aren already producing.

Click here to get the full story… along with our long list of backdoor Bitcoin strategies. It’s free.

Sponsored


An evaluation of the daily trading volume of Infinity Pharmaceuticals, Inc. (NASDAQ:INFI) indicates that the 3-month average is 3.51 Million. However, this figure has increased over the past 10 days to an average of 6.08 Million.

Get the hottest stocks to trade every day before the market opens 100% free. Click here now.

Currently, records show that 88.37 Million of the company’s shares remain outstanding. According to Thomson Reuters data, insiders hold 3.25% of outstanding shares, whereas institutions hold 48.98%. The stats also highlight that short interest as of January 28, 2021, stood at 705.51 Million shares, resulting in a short ratio of 0.38 at that time. From this, we can conclude that short interest is 1.1% of the company’s total outstanding shares. It is noteworthy that short shares in January were up slightly from the previous month’s figure, which was 551.5 Million. However, since the stock’s price has seen +72.17% year-to-date, investors’ interest is likely to be reignited due to its potential to move even higher.

Get The Best Stocks To Trade Every Day!

Join now to get the NewsHeater.com pre-market morning brief 100% free

LEAVE A REPLY

Please enter your comment!
Please enter your name here